TARDBP and proteostasis deficiencies: Studies are suggesting that people with certain gene mutations or variants in triggering receptor expressed on myeloid cells 2 (TREM2) and CD33, both highly expressed in microglia, have an increased risk of TDP-43 proteinopathies [27].